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Naturally, mammalian embryo resulting from the fertilized oocytes by sperm and develops to 
the zygote with diploid chromosome. Through the embryo engineering, mammalian embryo also 
could be produce by: nuclear transfer and parthenogenesis. Embryo produce by nuclear transfer 
method could develop to term with very limited results. However, parthenogenetic embryos could 
not develop to term because of the incorrect expression of imprinted genes (genomic imprinting). 
Embryonic Stem Cell (ESC) develops from isolation of Inner Cell Mass (ICM) from fertilized 
embryo in the blastocyst stage. Cell therapy using ESC is still has an ethical controversial because 
of the fertilized embryo has a competency to develop to term. Similarly, diploid parthenogenetic 
embryo has a potential source of ICM to produce ESC we called parthenogenesis Embryonic Stem 
Cell (pESC). The advantaged of pESC are: 1) it should no ethical controversial because the pESC 
obtained from the unfertilized embryos (resulted from activated oocytes) and, 2) it should less 
rejection because the pESC has only one set of major histocompatibility (MHC) antigens from 
female. 
 
